168 related articles for article (PubMed ID: 36056411)
1. Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome.
Hornby B; Thompson WR; Almuqbil M; Manuel R; Abbruscato A; Carr J; Vernon HJ
Orphanet J Rare Dis; 2022 Sep; 17(1):336. PubMed ID: 36056411
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.
Thompson WR; Manuel R; Abbruscato A; Carr J; Campbell J; Hornby B; Vaz FM; Vernon HJ
Genet Med; 2024 Apr; 26(7):101138. PubMed ID: 38602181
[TBL] [Abstract][Full Text] [Related]
3. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism.
Reid Thompson W; Hornby B; Manuel R; Bradley E; Laux J; Carr J; Vernon HJ
Genet Med; 2021 Mar; 23(3):471-478. PubMed ID: 33077895
[TBL] [Abstract][Full Text] [Related]
4. Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data.
Van den Eynde J; Chinni B; Vernon H; Thompson WR; Hornby B; Kutty S; Manlhiot C
Orphanet J Rare Dis; 2023 Apr; 18(1):76. PubMed ID: 37041653
[TBL] [Abstract][Full Text] [Related]
5. Functional exercise capacity, strength, balance and motion reaction time in Barth syndrome.
Hornby B; McClellan R; Buckley L; Carson K; Gooding T; Vernon HJ
Orphanet J Rare Dis; 2019 Jan; 14(1):37. PubMed ID: 30744648
[TBL] [Abstract][Full Text] [Related]
6. Barth syndrome cardiomyopathy: targeting the mitochondria with elamipretide.
Sabbah HN
Heart Fail Rev; 2021 Mar; 26(2):237-253. PubMed ID: 33001359
[TBL] [Abstract][Full Text] [Related]
7. Quality of life in Barth syndrome.
Kim AY; Vernon H; Manuel R; Almuqbil M; Hornby B
Ther Adv Rare Dis; 2022; 3():26330040221093743. PubMed ID: 37180415
[TBL] [Abstract][Full Text] [Related]
8. Temporal evolution of the heart failure phenotype in Barth syndrome and treatment with elamipretide.
Sabbah HN; Taylor C; Vernon HJ
Future Cardiol; 2023 Mar; 19(4):211-225. PubMed ID: 37325898
[TBL] [Abstract][Full Text] [Related]
9. A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy.
Karaa A; Haas R; Goldstein A; Vockley J; Cohen BH
J Cachexia Sarcopenia Muscle; 2020 Aug; 11(4):909-918. PubMed ID: 32096613
[TBL] [Abstract][Full Text] [Related]
10. Elamipretide for Barth syndrome cardiomyopathy: gradual rebuilding of a failed power grid.
Sabbah HN
Heart Fail Rev; 2022 Sep; 27(5):1911-1923. PubMed ID: 34623544
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.
Karaa A; Bertini E; Carelli V; Cohen BH; Enns GM; Falk MJ; Goldstein A; Gorman GS; Haas R; Hirano M; Klopstock T; Koenig MK; Kornblum C; Lamperti C; Lehman A; Longo N; Molnar MJ; Parikh S; Phan H; Pitceathly RDS; Saneto R; Scaglia F; Servidei S; Tarnopolsky M; Toscano A; Van Hove JLK; Vissing J; Vockley J; Finman JS; Brown DA; Shiffer JA; Mancuso M;
Neurology; 2023 Jul; 101(3):e238-e252. PubMed ID: 37268435
[TBL] [Abstract][Full Text] [Related]
12. Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with Leber Hereditary Optic Neuropathy: A Randomized Trial.
Karanjia R; Sadun AA
Ophthalmology; 2024 Apr; 131(4):422-433. PubMed ID: 37923251
[TBL] [Abstract][Full Text] [Related]
13. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy.
Karaa A; Haas R; Goldstein A; Vockley J; Weaver WD; Cohen BH
Neurology; 2018 Apr; 90(14):e1212-e1221. PubMed ID: 29500292
[TBL] [Abstract][Full Text] [Related]
14. Barth syndrome.
Jefferies JL
Am J Med Genet C Semin Med Genet; 2013 Aug; 163C(3):198-205. PubMed ID: 23843353
[TBL] [Abstract][Full Text] [Related]
15. Development and content validity of the Barth Syndrome Symptom Assessment (BTHS-SA) for adolescents and adults.
Gwaltney C; Stokes J; Aiudi A; Mazar I; Ollis S; Love E; Shields A
Orphanet J Rare Dis; 2021 Jun; 16(1):264. PubMed ID: 34108006
[TBL] [Abstract][Full Text] [Related]
16. Understanding the life experience of Barth syndrome from the perspective of adults: a qualitative one-on-one interview study.
Mazar I; Stokes J; Ollis S; Love E; Espensen A; Barth PG; Powers JH; Shields AL
Orphanet J Rare Dis; 2019 Nov; 14(1):243. PubMed ID: 31699126
[TBL] [Abstract][Full Text] [Related]
17. Reduced Muscle Strength in Barth Syndrome May Be Improved by Resistance Exercise Training: A Pilot Study.
Bittel AJ; Bohnert KL; Reeds DN; Peterson LR; de Las Fuentes L; Corti M; Taylor CL; Byrne BJ; Cade WT
JIMD Rep; 2018; 41():63-72. PubMed ID: 29654548
[TBL] [Abstract][Full Text] [Related]
18. Favorable outcomes after heart transplantation in Barth syndrome.
Li Y; Godown J; Taylor CL; Dipchand AI; Bowen VM; Feingold B
J Heart Lung Transplant; 2021 Oct; 40(10):1191-1198. PubMed ID: 34330606
[TBL] [Abstract][Full Text] [Related]
19. Impaired cardiac reserve and severely diminished skeletal muscle O₂ utilization mediate exercise intolerance in Barth syndrome.
Spencer CT; Byrne BJ; Bryant RM; Margossian R; Maisenbacher M; Breitenger P; Benni PB; Redfearn S; Marcus E; Cade WT
Am J Physiol Heart Circ Physiol; 2011 Nov; 301(5):H2122-9. PubMed ID: 21873497
[TBL] [Abstract][Full Text] [Related]
20. Impaired cardiac and skeletal muscle bioenergetics in children, adolescents, and young adults with Barth syndrome.
Bashir A; Bohnert KL; Reeds DN; Peterson LR; Bittel AJ; de Las Fuentes L; Pacak CA; Byrne BJ; Cade WT
Physiol Rep; 2017 Feb; 5(3):. PubMed ID: 28196853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
